Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Tolerability of Aumolertinib in European Participants with EGFR-mutated NSCLC
NCT07130916Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Time to Maximum Plasma Concentration, Maximum Plasma Concentration and 2 more. Started Dec 2024; status: recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07130916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07130916.